ホーム 計算ツール
代理店ログイン

阻害抗体

A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.

The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.

After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.

Targetmol provides 30 monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.

Cat. No. 製品名 CAS No. Purity Chemical Structure
T35396 Spartalizumab (anti-PD-1) 98%
T36652 Anti-MERS-3A1 mAb 98%
Anti-MERS-3A1 mAb (MERS-3A1) is a high-affinity human monoclonal IgG1 antibody derived from CHO cells. It effectively inhibits the interaction between the MERS-C...
T39595 Disitamab vedotin 2136633-23-1 98%
Disitamab vedotin (RC48) is a cleavable antibody-drug conjugate (ADC) that combines a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER...
T25593 Labetuzumab govitecan 1469876-18-3 98%
Labetuzumab govitecan is an anti-CEACAM5/SN-38 antibody-drug conjugate for therapy of refractory or relapsing metastatic colorectal cancer.
T9931 Meplazumab 2413715-21-4 98%
meplazumab is a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia.
T39057 Rozanolixizumab 1584645-37-3 98%
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing path...
T35391 Vibostolimab (anti-TIGIT) 98%
T12706 Reslizumab 241473-69-8 98%
Reslizumab is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma.
T36656 Anti-Spike-RBD Single Domain mAb 98%
The Anti-Spike-RBD Single Domain mAb is a monoclonal antibody derived from CHO cells in Alpaca. It is composed of VHH-huFc and exhibits a strong affinity for the...
T35389 Sarilumab (anti-IL-6Rα) 98%
T9922 Matuzumab 339186-68-4 98%
Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR frequently associated with the growth of blood vessels in ...
T36655 Anti-Spike-RBD mAb 98%
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of spike protein and ACE2 is a potential therapeutic approach f...
T9925 Ofatumumab 679818-59-8 98%
Ofatumumab is a fully human monoclonal antibody to CD20 which appears to inhibit early-stage B lymphocyte activation
T36647 Trastuzumab emtansine 1018448-65-1 98%
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab wit...
T35392 Tiragolumab (anti-TIGIT) 98%
T38951 Isatuximab 1461640-62-9 98%
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38 , a protein highly expressed on hematological malignant cells, inclu...
T9928 Ranibizumab 347396-82-1 98%
Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and...
T39730 Datopotamab deruxtecan 2238831-60-0 98%
Datopotamab deruxtecan (DS-1062; Dato-DXd) is an antibody-drug conjugate (ADC) that specifically targets trophoblast cell surface antigen 2 (TROP2). This compoun...
T10497 Benralizumab 1044511-01-4 98%
Benralizumab (MEDI-563) is an IL-5Rα-directed cytolytic monoclonal antibody that induces rapid, direct and nearly complete depletion of eosinophils via enhanced ...
T38105 Ixekizumab 1143503-69-8 98%
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL...
Spartalizumab (anti-PD-1)
T35396
Anti-MERS-3A1 mAb
T36652
Anti-MERS-3A1 mAb (MERS-3A1) is a high-affinity human monoclonal IgG1 antibody derived from CHO cells. It effectively inhibits the interaction between the MERS-C...
Disitamab vedotin
T39595
Disitamab vedotin (RC48) is a cleavable antibody-drug conjugate (ADC) that combines a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER...
Labetuzumab govitecan
T25593
Labetuzumab govitecan is an anti-CEACAM5/SN-38 antibody-drug conjugate for therapy of refractory or relapsing metastatic colorectal cancer.
meplazumab
T9931
meplazumab is a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia.
Rozanolixizumab
T39057
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing path...
Vibostolimab (anti-TIGIT)
T35391
Reslizumab
T12706
Reslizumab is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma.
Anti-Spike-RBD Single Domain mAb
T36656
The Anti-Spike-RBD Single Domain mAb is a monoclonal antibody derived from CHO cells in Alpaca. It is composed of VHH-huFc and exhibits a strong affinity for the...
Sarilumab (anti-IL-6Rα)
T35389
Matuzumab
T9922
Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR frequently associated with the growth of blood vessels in ...
Anti-Spike-RBD mAb
T36655
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of spike protein and ACE2 is a potential therapeutic approach f...
Ofatumumab
T9925
Ofatumumab is a fully human monoclonal antibody to CD20 which appears to inhibit early-stage B lymphocyte activation
Trastuzumab emtansine
T36647
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab wit...
Tiragolumab (anti-TIGIT)
T35392
Isatuximab
T38951
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38 , a protein highly expressed on hematological malignant cells, inclu...
Ranibizumab
T9928
Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and...
Datopotamab deruxtecan
T39730
Datopotamab deruxtecan (DS-1062; Dato-DXd) is an antibody-drug conjugate (ADC) that specifically targets trophoblast cell surface antigen 2 (TROP2). This compoun...
Benralizumab
T10497
Benralizumab (MEDI-563) is an IL-5Rα-directed cytolytic monoclonal antibody that induces rapid, direct and nearly complete depletion of eosinophils via enhanced ...
Ixekizumab
T38105
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL...
1 2 3